1. Alemtuzumab: the mechanisms of differential sensitivity and resistance
- Author
-
Loeff, F.C., Falkenburg, J.H.F., Halkes, C.J.M., Jedema, I., Kooten, C. van, Ham, S.M. van, Zeerleder, S.S., and Leiden University
- Subjects
Therapeutic antibody ,PIGH ,fungi ,GPI-anchor ,PIGA ,Alemtuzumab ,Complement-dependent cytoxicity ,B-cell acute lymphoblastic leukemia ,Allogeneic stem cell transplantation - Abstract
Alemtuzumab (ALM) is a cytotoxic monoclonal antibody that is used as a therapeutic agent in a variety of clinical settings. The target antigen for ALM is CD52, which is highly expressed on the membrane of mature lymphocytes, but not or only marginally on hematopoietic stem cells, red blood cells, and non-hematopoietic tissues. As such, ALM can be administered for the purpose of lymphocyte depletion with no or only minimal toxicity to other tissues. In this thesis, the mechanism of action of ALM was investigated in the context of two clinical settings, i.e. T-cell depletion before allogeneic stem cell transplantation (alloSCT) and depletion of malignant cells in B lymphoblastic leukemia (B-ALL).
- Published
- 2021